REGENXBIO Confirms Major Milestone Reached in Crucial Study of RGX-121 as Therapy for MPS II, Successfully Hitting Primary Goal.

The initial FOLFIRINOX protocol for PDAC carries a high FN risk; pegfilgrastim mitigates this, but optimal duration is uncertain.

Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.

Dopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira.

Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.

LY3537982: A Potent Oral Inhibitor for KRAS G12C Mutation in GI Tumors - Results from 2024 ASCO-GI LOXO-RAS-20001 Phase 1 Study.

Scholar Rock's Study Reveals SRK-439's Potential Influence on Muscle Mass and Metabolic Health in Weight Loss Efforts.

Naltrexone, an opioid antagonist, has been utilized for treating addiction to both drugs and alcohol.

Orchard Therapeutics Reveals Enrollment of Initial Participant in Key Study of OTL-203 Targeting Hurler's Syndrome in MPS-I.

The phase II trial of mFOLFIRINOX, followed by hepatic infusion of floxuridine & dexamethasone with mFOLFIRI as first-line treatment in intrahepatic cholangiocarcinoma patients (HELIX-1), was presented at 2024 ASCO_GI on Jan 18.

Rani Therapeutics Reports Encouraging Initial Outcomes from Phase 1 Trial of Oral RT-111, an Anti-IL-12/23 Antibody.

Minoxidil, found in LONITEN Tablets manufactured by Pfizer, is a peripheral vasodilator that is commonly used to treat hypertension and alopecia.